Financial Times FT.com

Vertex's lead drug telaprevir for the treatment of Hepatitis C will have to be monitored for the potential emergence of drug resistance, physicians say

By Kimberly Ha in New York

Published: January 31 2008 14:45 | Last updated: January 31 2008 14:45

Copyright The Financial Times Limited 2009. You may share using our article tools. Please don't cut articles from FT.com and redistribute by email or post to the web.

Email options

The information entered on this page will not be used to send unsolicited email, and will not be sold to a 3rd party.Terms of use |Privacy policy

* required fields



(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)





"FT" and "Financial Times" are trademarks of The Financial Times.Privacy policy | Terms
© Copyright The Financial Times Ltd 2009